Xantos to Use Atugen s RNAi Compounds for Cancer Target Validation

genomeweb
360dx

Xantos to Use Atugen s RNAi Compounds for Cancer Target Validation

Apr 15, 2005

NEW YORK, April 15 (GenomeWeb News) - Xantos Biomedicine today announced an agreement to use Atugen's atuRNAi short interfering RNAi compounds to validate an angiogenic target in animal studies.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Geisinger Exome Study IDs Breast Cancer Risk Variants That May Not Have Been Detected in Routine Care
Genetic Study Identifies Five Forms of Type 2 Diabetes
In Brief This Week: Agilent, Bionano Genomics, Opko Health, and More
People in the News: Joseph Jimenez, Marco Casarin, Steven Riedmuller, More
Biocept Plans to Sell $2.5M in Stock, Warrants
Highly Efficient Genome Editing Method Reveals Fitness of Genetic Variants in Yeast

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu